Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.

Landmark post-treatment ctDNA detection was associated with relapse (HR 20.7, 95% CI 7.7-55.5, P<0.0001). All 11 patients with landmark detection progressed, at a median of 121 days after detection, including all 8 who relapsed within 300 days of treatment. Among 27 patients who progressed, post-treatment ctDNA was detected in 17, with a median lead time of 203 days (up to 741 days).

ASCO Annual Meeting 2021